Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Oct 17, 2024

BUY
$0.68 - $0.97 $152,239 - $217,164
223,881 New
223,881 $163,000
Q1 2024

Aug 16, 2024

SELL
$0.68 - $0.97 $65,231 - $93,051
-95,929 Reduced 30.0%
223,881 $163,000
Q1 2024

May 15, 2024

SELL
$0.68 - $0.97 $65,231 - $93,051
-95,929 Reduced 30.0%
223,881 $163,000
Q4 2023

Aug 16, 2024

BUY
$0.72 - $1.13 $230,263 - $361,385
319,810 New
319,810 $297,000
Q4 2023

Feb 13, 2024

SELL
$0.72 - $1.13 $47 - $74
-66 Reduced 0.02%
319,810 $297,000
Q3 2023

Nov 15, 2023

SELL
$0.91 - $2.29 $285,603 - $718,716
-313,850 Reduced 49.52%
319,876 $310,000
Q2 2023

Aug 14, 2023

SELL
$2.15 - $3.16 $300,828 - $442,147
-139,920 Reduced 18.09%
633,726 $1.36 Million
Q1 2023

May 15, 2023

SELL
$2.16 - $3.47 $298,868 - $480,126
-138,365 Reduced 15.17%
773,646 $2.17 Million
Q4 2022

Feb 14, 2023

SELL
$1.73 - $2.95 $5,158 - $8,796
-2,982 Reduced 0.33%
912,011 $2.05 Million
Q3 2022

Nov 14, 2022

SELL
$2.39 - $3.96 $141,495 - $234,443
-59,203 Reduced 6.08%
914,993 $2.19 Million
Q2 2022

Oct 27, 2022

BUY
$1.75 - $10.44 $154,672 - $922,728
88,384 Added 9.98%
974,196 $2.83 Million
Q2 2022

Aug 15, 2022

BUY
$1.75 - $10.44 $154,672 - $922,728
88,384 Added 9.98%
974,196 $2.83 Million
Q1 2022

Oct 27, 2022

SELL
$6.7 - $10.23 $592,172 - $904,168
-88,384 Reduced 9.07%
885,812 $8.23 Million
Q1 2022

May 13, 2022

BUY
$6.7 - $10.23 $2.42 Million - $3.69 Million
361,094 Added 68.82%
885,812 $8.23 Million
Q4 2021

Feb 14, 2022

BUY
$9.43 - $17.14 $538,236 - $978,299
57,077 Added 12.21%
524,718 $5 Million
Q3 2021

Nov 15, 2021

BUY
$17.37 - $27.92 $8.12 Million - $13.1 Million
467,641 New
467,641 $8.36 Million

Others Institutions Holding BNR

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0

About Burning Rock Biotech Ltd


  • Ticker BNR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 105,188,000
  • Market Cap $705M
  • Description
  • Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and p...
More about BNR
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.